Urologic Neoplasms: Clinical Trials

74 trials for Urologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 16 unknown, 11 recruiting, 8 terminated. 74 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 474Completed 34, Unknown 16, Recruiting 11, Terminated 8, Not yet recruiting 3, Withdrawn 2

Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms

Trials (filtered) newest first · largest first

All 74 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Treatment Delivery Preference In People With Kidney Cancer
Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer
Phase 4RecruitingMemorial Sloan Kettering Cancer Center402026-09-242026-10-16
Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
Experimental - Elderly, Breast Cancer
Phase 4Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris7942026-09-012026-09-03
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Phase 4RecruitingOHSU Knight Cancer Institute1602026-04-242026-10-13
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Accelerometry, BCG Solution, Electronic Health Record Review - Non-Muscle Invasive Bladder Carcinoma
Phase 4RecruitingOhio State University Comprehensive Cancer Center402026-02-262026-03-16
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM) - Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Phase 4RecruitingUniversity of Roma La Sapienza3272025-12-222025-12-31
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma
Phase 4RecruitingCentre Francois Baclesse832025-10-012026-07-14
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy - Renal Cell Cancer, Kidney Neoplasm
Phase 4RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS4092025-06-152025-07-03
Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
Mitomycin c - Non-Muscle Invasive Bladder Cancer
Phase 4RecruitingJakob Kristian Jakobsen2722025-06-012025-10-03
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer
Phase 4RecruitingGustave Roussy, Cancer Campus, Grand Paris502025-05-162025-09-24
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Phase 4RecruitingMayo Clinic752025-01-082026-10-01
The Impact of PDD During TURB for NMIBC
Transurethral resection of the bladder performed with PDD tecnique and Hexvix - Bladder Cancer
Phase 4Not yet recruitingA.O.U. Città della Salute e della Scienza3002024-09-012024-08-12
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
nadofaragene firadenovec - Bladder Cancer, Ta/T1
Phase 4WithdrawnFerring Pharmaceuticals2024-06-172024-11-22
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma
Phase 4UnknownUniversity Medical Center Groningen302024-05-012023-11-29
Fluid Challenge and Plasma Volume, During Surgery
acetated Ringers, albumin 5%, albumin 20% - Colorectal Cancer, Urologic Cancer
Phase 4CompletedJoachim Zdolsek652023-10-232026-11-10
Preop Laxatives in Robotic Urologic Surgery
Polyethylene Glycol 3350 - Prostate Cancer, Kidney Cancer
Phase 4RecruitingChad R. Tracy2402023-06-012025-05-30
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
Metformin Hydrochloride 500 MG - Muscle-Invasive Bladder Carcinoma
Phase 4UnknownCairo University782023-06-012024-08-20
Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBC
Bacillus Calmette Guerin, Gemcitabine HCL (Gemzar) - Urothelial Carcinoma Bladder, Sperm Count, Low
Phase 4CompletedAssiut University862023-04-012026-10-29
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
BCG combined with Tislelizumab - Non-muscle-invasive Bladder Cancer
Phase 4UnknownRuijin Hospital422022-10-092022-10-14
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
Disitamab Vedotin for Injection,Penpulimab Injection - Bladder Cancer
Phase 4UnknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen University482022-09-012022-08-04
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
low-dose neuroleptanalgesia, Placebo - Stomach Neoplasms, Colonic Neoplasms
Phase 4UnknownRenJi Hospital2002021-10-052021-10-06

Showing 20 of 74. Sign in to see all of them.

Narrower conditions

Urinary Bladder Neoplasms (27)  ·  Carcinoma, Renal Cell (26)  ·  Kidney Neoplasms (21)  ·  Non-Muscle Invasive Bladder Neoplasms (9)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Lung Neoplasms (5)  ·  Liver Neoplasms (4)  ·  Neoplasms (4)  ·  Prostatic Neoplasms (4)  ·  Carcinoma, Hepatocellular (3)  ·  Neoplasm Metastasis (3)  ·  Recurrence (3)  ·  Stomach Neoplasms (3)  ·  Breast Neoplasms (2)

Broader conditions

Female Urogenital Diseases (74)  ·  Female Urogenital Diseases and Pregnancy Complications (74)  ·  Male Urogenital Diseases (74)  ·  Neoplasms by Site (74)  ·  Urogenital Diseases (74)  ·  Urogenital Neoplasms (74)  ·  Urologic Diseases (74)  ·  Neoplasms (70)  ·  Kidney Diseases (40)  ·  Neoplasms by Histologic Type (38)  ·  Neoplasms, Glandular and Epithelial (36)  ·  Carcinoma (35)  ·  Urinary Bladder Diseases (35)  ·  Adenocarcinoma (26)

Interventions

Nivolumab (7)  ·  Everolimus (5)  ·  Sunitinib (5)  ·  5-aminolevulinic acid hexyl ester (3)  ·  BCG Vaccine (3)  ·  Mitomycin (3)  ·  pazopanib (3)  ·  Anesthesia, Epidural (2)  ·  Doxorubicin (2)  ·  Epirubicin (2)  ·  Fentanyl (2)  ·  Gemcitabine (2)  ·  Ipilimumab (2)  ·  Midazolam (2)  ·  Neostigmine (2)

Sponsors

Bristol-Myers Squibb (4)  ·  Mansoura University (4)  ·  Novartis Pharmaceuticals (4)  ·  Medical University of Warsaw (3)  ·  Assiut University (2)  ·  Gustave Roussy, Cancer Campus, Grand Paris (2)  ·  M.D. Anderson Cancer Center (2)  ·  iOMEDICO AG (2)  ·  A.O.U. Città della Salute e della Scienza (1)  ·  Ankara Training and Research Hospital (1)  ·  Ankara University (1)  ·  Asan Medical Center (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Azienda Ospedaliera "Sant'Andrea" (1)  ·  Bayer (1)

Countries

United States (19)  ·  Egypt (7)  ·  France (6)  ·  China (5)  ·  Germany (4)  ·  Turkey (Türkiye) (4)  ·  Denmark (3)  ·  India (3)  ·  Italy (3)  ·  Poland (3)  ·  Russia (3)  ·  Sweden (3)  ·  Netherlands (2)  ·  South Korea (2)  ·  Algeria (1)

Top investigators

Ahmed Mosbah, MD (3)  ·  Ahmed Elhussein, MBBCH (2)  ·  Ahmed Elkarta, MBBCH (2)  ·  Karolina Dobronska, MD (2)  ·  Abdelwahab R. Hashem, Msc (1)  ·  Ahmed Harraz, MD (1)  ·  Ahmed M Eltaher, professor (1)  ·  Ahmed Moeen (1)  ·  Andrea Tubaro (1)  ·  Anne Sophie P. Kancir, MD PhD (1)  ·  Atallah A. Shaaban, MD (1)

Results publications

PMID 21266057, PMID 21319349, PMID 21655015, PMID 21775497, PMID 22241828, PMID 22704310, PMID 23170127, PMID 23733379, PMID 23759377, PMID 23982601, PMID 25466382, PMID 27101285, PMID 30448030, PMID 31780139, PMID 32738823, PMID 33070307, PMID 33300144, PMID 33537703, PMID 33552568, PMID 34611902, PMID 34791718, PMID 35210307, PMID 36104138, PMID 36223555, PMID 37230961, PMID 38842053, PMID 39397266, PMID 39868569, PMID 40279497, PMID 40319155, PMID 40375148, PMID 41801644, PMID 42433301

NIH funding

2015 (1), 2017 (1), 2025 (1), R01CA091912 (1)